BioCentury | Apr 7, 2014
Clinical News

Pandemic influenza vaccine regulatory update

Takeda said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA for cell-culture based pandemic influenza vaccines produced at Takeda's Hikari, Japan plant. The approval covers an H5N1 avian influenza vaccine and a...
BioCentury | Mar 31, 2014
Clinical News

Emulsified Influenza HA Vaccine regulatory update

...Japan's Ministry of Health, Labor and Welfare (MHLW) approved Emulsified Influenza HA Vaccine, an H5N1 adjuvanted prophylactic pandemic influenza...
...BioCentury, Oct. 5, 2009). Kaketsuken , Kumamoto, Japan GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Emulsified Influenza HA Vaccine...
BioCentury | Jun 24, 2013
Clinical News

Cell culture-based pandemic influenza vaccine regulatory update

...subsidiary submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for a cell culture-based pandemic influenza vaccine...
...being developed for use in Japan. Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Product: Cell culture-based pandemic influenza vaccine...
BioCentury | Jun 20, 2013
Company News

Daiichi seeking Japanese approval of pandemic flu vaccine

...subsidiary submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for a cell culture-based pandemic influenza vaccine...
BioCentury | Apr 8, 2013
Clinical News

Cell culture-based pandemic influenza vaccine regulatory update

...BioCentury, Oct. 5, 2009). Kaketsuken , Kumamoto, Japan GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Cell culture-based pandemic influenza vaccine...
BioCentury | Apr 8, 2013
Clinical News

Pandemic influenza vaccine regulatory update

Takeda submitted NDAs to Japan's Ministry of Health, Labor and Welfare (MHLW) for cell-culture based pandemic influenza vaccines produced at Takeda's plant in Hikari, Japan. The submission covers an H5N1 avian influenza vaccine and a...
BioCentury | Sep 24, 2012
Clinical News

Cell culture-based pandemic influenza vaccine: Phase III started

...Japan GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Cell culture-based pandemic influenza vaccine Business: Infectious Molecular target: NA Description: Cell culture-based pandemic influenza vaccine...
BioCentury | May 28, 2012
Clinical News

Cell culture based pandemic influenza vaccine: Phase II started

Vivalis S.A. (Euronext:VLS, Nantes, France) said Kaketsuken began in April a Japanese Phase II trial to evaluate a cell culture-based pandemic flu vaccine. In 2009, GlaxoSmithKline and Kaketsuken (formerly the Chemo-Sero-Therapeutic Research Institute) partnered to...
BioCentury | Jan 22, 2007
Company News

Iomai, GlaxoSmithKline, Novartis, U.S. Department of Health and Human Services infectious news

...NVS will receive $54.8 million over five years to develop its MF59 adjuvant in a cell culture-based pandemic influenza vaccine...
BioCentury | Jan 18, 2007
Top Story

HHS awards $132.5M for avian flu vaccines

...SWX:NOVN) will receive $54.8 million over five years to develop its MF59 adjuvant in a cell culture-based pandemic influenza vaccine...
Items per page:
1 - 10 of 10